Serum sCD25 Protein as a Predictor of Lack of Long-Term Benefits from Immunotherapy in Non-Small Cell Lung Cancer: A Pilot Study

Serum sCD25 Protein as a Predictor of Lack of Long-Term Benefits from Immunotherapy in Non-Small Cell Lung Cancer: A Pilot Study

Prognosis of advanced non-small cell lung carcinoma (NSCLC) is poor. Even though it can improve with anti-PD-1/PD-L1 agents, most patients do not respond to treatment. We hypothesized that the serum soluble form of the unit α of the interleukin-2 receptor (sCD25) could be used as a biomarker of succ...

Full description

Bibliographic Details
Main Authors: Anna Siemiątkowska, Maciej Bryl, Katarzyna Kosicka-Noworzyń, Jakub Tvrdoň, Iwona Gołda-Gocka, Aleksander Barinow-Wojewódzki, Franciszek K. Główka
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
biomarkers
sCD25
atezolizumab
pembrolizumab
anti-PD-1/PD-L1
Online Access:https://www.mdpi.com/2072-6694/13/15/3702

Internet

https://www.mdpi.com/2072-6694/13/15/3702

Similar Items